Plain-English translation of NCT07811726 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether NT-101 eye drops can help treat wet age-related macular degeneration (AMD), a condition that damages the center of your vision as you age. You would receive either the medication or a placebo (dummy eye drops with no active ingredient), and researchers would measure how well it works and whether it's safe. About 66 people will participate in this study.
Currently, wet AMD is treated with injections into the eye, which can be uncomfortable and burdensome for patients. This trial is exploring whether eye drops might offer a gentler alternative that could slow vision loss and improve quality of life.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for a screening visit, then start using the eye drops twice daily for 12 weeks (either the new medication or placebo). You would return to the clinic at weeks 4, 8, and 12 for eye exams and imaging tests (like OCT scans and photographs). After treatment ends, you would have one final follow-up visit 4 weeks later. Throughout the study, your eye pressure, vision, and any side effects would be carefully monitored.
AI-generated summary from trial data · Sep 15, 2026 · Not medical advice
United States